Chronic kidney diseases always develop to chronic renal failure (CRF) or end-stage renal diseases eventually, and associated with 10 to 20-fold increased incidence in …
YC Chuang, MS Wu, YK Su, KM Fang - Cardiovascular Diabetology, 2012 - Springer
Background It has been suggested that the antioxidant properties of olmesartan (OLM), an angiotensin II type 1 receptor (AT 1 R) blocker, contribute to renal protection rather than …
J Stegbauer, SA Potthoff, I Quack… - British journal of …, 2011 - Wiley Online Library
BACKGROUND AND PURPOSE ApolipoproteinE‐deficient [apoE (−/−)] mice, a model of human atherosclerosis, develop endothelial dysfunction caused by decreased levels of nitric …
SI Yamagishi, Y Inagaki, T Okamoto, S Amano… - Kidney international, 2003 - Elsevier
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Background We have shown previously that OPB …
W Zhang, F Hou, S Liu, Z Guo… - Chinese Journal of …, 1997 - pesquisa.bvsalud.org
Objective To test the hypothesis that advanced glycosylation end products (AGEs) increase cellular inflammation in atherosclerotic plaques. Methods Fifty rabbits were randomly …
Y Yuan, H Sun, Z Sun - Lipids in Health and Disease, 2017 - Springer
Background Advanced glycation end products (AGEs) are pathogenic factors of diabetic nephropathy (DN), causing renal damage in various ways. The aim of this study is to …
Y Ying, CAI Guang-Yan - Jie Fang Jun Yi Xue Za Zhi, 2020 - search.proquest.com
Advanced glycation end products (AGE) are stable compounds produced by spontaneous non-enzymatic reaction between reducing sugars and proteins, and have been proven …